GLP1R and type 2 diabetes mellitus: Of note, new therapeutic options for patient with type 2 diabetes including GLP-1 receptor agonists and SLGT-2 inhibitors appear to confer cardiovascular risk protection through diverse mechanisms, but these may include altering lipid profiles [27,28].